NXGLHealthcare · Medical Instruments & Supplies

NXGL Stock Forecast: NexGel, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026

$4.01

−10.49% on the day

The 1 Wall Street analysts covering NexGel, Inc. hold a median 12-month price target of $2 — -50.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 4 Nov 2026 — in the weakest quartile.

Market cap

$2.0M

Ticker Nerd rank

15/ 100

Median analyst target

$2.00

Analysts covering

Revenue$3.7M+27.8% y/y

Operating income−$2.5M

Net income−$3.6M

Free cash flow−$8.8M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−0.5%

+15.2%

YTD

−87.5%

−90.9%

From 52W high

−91.9%

From 52W low

+33.7%

$50

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

NXGL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NexGel, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026

15/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Quality

Accruals

Volatility

Value

Momentum

Issuance

Growth

Size (90): Smaller than most of the companies we track.

Growth (6): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NXGL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NXGL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

0 Buy1 Hold0 Sell

Low $2.00Median $2.00High $2.00

The green dot is the last close — the median target sits −50.1% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
24 Aug 2026	Maxim Group	Downgrade	Hold	—
12 Mar 2026	Maxim Group	Maintains	Buy	$6.00 → $2.00
12 Mar 2026	Maxim Group	Maintains	Buy	—
25 Feb 2022	Maxim Group	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NXGL appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

NXGL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, NexGel, Inc. returned −90.9% against +14.8% for the S&P 500, dividends included.

NXGL vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NXGL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

NexGel, Inc. (NXGL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −10.6×
Price / sales: 0.2×
Price / book: 0.4×
EV / EBITDA: −2.3×

Growth & margins

Revenue growth (YoY): 27.8%
Earnings growth (YoY): 27.8%
Gross margin: 30.1%
Operating margin: −68.0%
Net margin: −51.3%

Returns & dividend

Return on equity: −115.1%
Return on assets: −18.7%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NexGel, Inc. (NXGL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

NexGel, Inc. has a market value of $2.0M and an enterprise value of $9.7M.
Revenue in the twelve months to 30 June 2026: $12.1M. The latest quarter grew 27.8% year on year.
Net income over the same four quarters: −$6.1M, a −50.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$9.8M.
Shares outstanding: 9.2M.
Trailing P/E: −10.6×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
NexGel, Inc. employs 19 people — $635K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

NXGL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies

Company	Market cap	TKN rank
NXGLNexGel, Inc.	$2.0M	15
FEMYFemasys, Inc.	$12.1M	33
CUPRCuprina Holdings (Cayman) Ltd.	$11.3M	4
RGNTRegentis Biomaterials Ltd.	$9.3M	8
BNGOBionano Genomics, Inc.	$16.6M	76
RVPRetractable Technologies, Inc.	$16.9M	59
LUCYInnovative Eyewear, Inc.	$7.3M	24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NexGel, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NXGL news & analysis

NEXGEL Regains Compliance with Nasdaq Listing Requirement

GlobeNewsWire · 27 Oct 2026positive

NEXGEL said Nasdaq notified it that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), and the matter is closed. Its common stock will continue to be listed and traded on the Nasdaq Capital Market.

Why it matters — NXGL watchers may note that the company has resolved this Nasdaq listing-compliance matter and its listing will continue on the Nasdaq Capital Market.

NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript

Seeking Alpha · 25 Sept 2026neutral

NEXGEL, Inc. discussed a strategic platform reorganization and a refocus on medical device and biomedical innovation, as covered in a Seeking Alpha transcript of the company's presentation. The item outlines the company's stated strategic direction regarding its platforms and focus areas.

Why it matters — A NXGL watcher would care because the reorganization and refocus signal a shift in the company's strategic direction that could reshape its platform priorities and innovation pipeline.

NEXGEL Announces Dial-In Details for Investor Update Call

GlobeNewsWire · 23 Sept 2026neutral

NEXGEL, Inc. announced dial-in details for its previously announced investor update call scheduled for September 24, 2026, at 4:15 p.m. Eastern Time. The company, which provides medical technology solutions for clinicians and patients, released this information via GlobeNewsWire.

Why it matters — Investors and NXGL watchers will need these dial-in details to access the upcoming investor update call where the company is expected to provide updates.

NEXGEL Announces Date for Investor Update Call

GlobeNewsWire · 16 Sept 2026neutral

NEXGEL, Inc. announced that its investor update call, originally referenced in its August 17, 2026 earnings release, will now be hosted on September 24, 2026, at 4:15 p.m. Eastern Time. The call had previously been expected on or around September 15, 2026.

Why it matters — NEXGEL watchers will want to note the revised date for the scheduled investor update call to stay informed on the company's corporate communications.

FAQ

Frequently asked questions about NXGL stock

What is the NXGL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering NexGel, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NXGL stock a buy right now?

Of the 1 analysts covering NexGel, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NexGel, Inc. 15 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NXGL?

As at 4 Nov 2026, NexGel, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will NXGL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies -50.1% from the last close, and Ticker Nerd's factor model ranks NexGel, Inc. 15 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NXGL stock forecast for 2030?

No analyst covering NexGel, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.

How has NXGL stock performed over the past year?

NexGel, Inc. returned -90.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NexGel, Inc. do?

What is the latest news on NXGL?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "NEXGEL Regains Compliance with Nasdaq Listing Requirement". NEXGEL said Nasdaq notified it that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), and the matter is closed. Its common stock will continue to be listed and traded on the Nasdaq Capital Market.

Company

About NexGel, Inc.

NexGel Inc. is a healthcare and consumer products company that develops and manufactures high-water-content hydrogels and gel-based formulations for wound care, medical diagnostics, transdermal drug delivery, cosmetics, and over-the-counter remedies. The company’s platform focuses on ultra-gentle, skin-friendly materials designed for applications that require comfortable wear, controlled delivery, and broad formulation flexibility. NexGel serves both healthcare and consumer markets through products used in blister care, pain relief, beauty, and cosmetic applications, while also supporting contract manufacturing relationships with other consumer health companies. Its business is organized around hydrogel manufacturing and converting and packaging operations, reflecting a mix of proprietary material science and outsourced product support services. Based in Langhorne, Pennsylvania, NexGel plays a niche role in the specialty materials segment of the healthcare market.

CEO Mr. Brian J. Kieser CPA · 19 employees · United States · https://nexgel.com